SLC5A2 and type 1 diabetes mellitus: In the DEPICT-1 study, the use of a SGLT2 inhibitor (Dapagliflozin 5.0 mg once a day) was accompanied by a 2.96 kg weight loss at 24 weeks compared to placebo in people with T1DM [25].